Background: Respiratory disease is the major cause of mortality in cystic fibrosis (CF) patients and inhaled antibiotic therapy may contribute to the stabilization of lung function. Objectives: This is a small, open, uncontrolled, observational study of clinical experience obtained with 2 years of maintenance treatment with inhaled tobramycin in 12 children and adolescents with CF. Methods: Twelve subjects aged 6–18 years infected by Pseudomonas aeruginosa were qualified for treatment with inhaled tobramycin. Pulmonary function, weight and height, clinical status, and chest X-ray were continually monitored. After an active 2-year treatment period, results of all measured parameters in our patients were compared with their previous results (2-year period before treatment with tobramycin). Results: During 2 years before treatment with tobramycin solution for inhalation (TOBI), pulmonary function decline was observed, the median value of FEV1 change was –7.6% (lower quartile –13.1, upper quartile –5.9). After 2 years of treatment, FEV1 percent predicted value declined by 1.5% (lower quartile –11.1, upper quartile 3.7) from baseline; 2 years of TOBI therapy significantly reduced lung function decline (p = 0.049). There were no significant changes in thoracic gas volume and specific airway resistance before and after treatment. Two years of TOBI therapy significantly improved body mass index (p = 0.02). TOBI treatment significantly delayed progression of pulmonary X-ray changes assessed by Brasfield score (p = 0.02). Conclusions: We found that patients with CF can gain substantial benefits from long-term TOBI treatment, including reduced pulmonary function decline, delayed progression of pulmonary X-ray changes and improved weight gain in growing children and adolescents.

Keywords:
Cystic fibrosis, Inhaled drug therapy, Nutritional status, Pulmonary function tests, X-ray
1.
Henry RL, Mellis CM, Petrovic L: Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158–161.
2.
Kerem E, Reisman J, Corey M, Canny GJ, Levison H: Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187–1191.
3.
Gustafsson PM: Commentary: early looks into the ‘silent lung zones’ of young subjects with cystic fibrosis. Respiration 2000;67:489–490.
4.
Koch C, Høiby N: Diagnosis and treatment of cysticfibrosis. Respiration 2000;67:239–247.
5.
Frederiksen B, Koch C, Hoiby N: Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;5:330–335.
6.
Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23–30.
7.
Moss RB: Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55–63.
8.
Bowman CM: The long-term use of inhaled tobramycin in patients with cystic fibrosis. J Cyst Fibros 2002;1:194–198.
9.
European Respiratory Society Working Party: Standardization of lung function testing. Eur Respir J 1993;6(suppl):5–100.
10.
Malinowski A, Chlebna-Sokol D: Lodz Child: Study Methods and Reference Values of Biological Development. Lodz, Ankal, 1998.
11.
Brasfield D, Hilks G, Soong S, Tiller RE: The chest roentgenogramin cystic fibrosis: a new scoring system. Pediatrics 1979;63:23–29.
12.
Quittner AL, Buu A: Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002;33:269–276.
13.
Hodson ME, Gallagher CG, Govan JR: A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658–664.
14.
Grzincich GL, Miano A, Pisi G, Spaggiari C, Tripodi MC: Effect of TOBI continuous therapy on pulmonary function in CF patients. J Cyst Fibros 2005;4:S53.
15.
Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP: Outcomes of adults with cysticfibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006;73:27–33.
16.
Aaron SD: Pseudomonas aeruginosa and cystic fibrosis - a nasty bug gets nastier. Respiration 2006;73:16–17.
17.
Koscik RE, Kosorok MR, Farrell PM, Collins J, Peters ME, Laxova A, Green CG, Zeng L, Rusakow LS, Hardie RC, Campbell PW, Gurney JW: Wisconsin cystic fibrosis chest radiograph scoring system: validation and standardization for application to longitudinal studies. Pediatr Pulmonol 2000;29:457–467.
18.
Terheggen-Lagro S, Truijens N, van Poppel N, Gulmans V, van der Laag J, van der Ent C: Correlation of six different cystic fibrosis chest radiograph scoring systems with clinical parameters. Pediatr Pulmonol 2003;35:441–445.
19.
Bell SC, Bowerman AR, Davies CA, Campbell IA, Shale DJ, Elborn JS: Nutrition in adults with cystic fibrosis. Clin Nutr 1998;17:211–215.
20.
Bakker W: Nutritional state and lung disease in cystic fibrosis. Neth J Med 1992;41:130–136.
21.
Kraemer R, Aebi C, Aebischer CC, Gallati S: Early detection of lung disease and its association with the nutritional status, genetic background and life events in patients with cystic fibrosis. Respiration 2000;67:477–490.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.